378 related articles for article (PubMed ID: 23594862)
1. Targeting cancer stem cells for treatment of glioblastoma multiforme.
Cho DY; Lin SZ; Yang WK; Lee HC; Hsu DM; Lin HL; Chen CC; Liu CL; Lee WY; Ho LH
Cell Transplant; 2013; 22(4):731-9. PubMed ID: 23594862
[TBL] [Abstract][Full Text] [Related]
2. Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Daniele S; Zappelli E; Natali L; Martini C; Trincavelli ML
Cell Death Dis; 2014 Nov; 5(11):e1539. PubMed ID: 25429616
[TBL] [Abstract][Full Text] [Related]
3. Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme.
Borovski T; Beke P; van Tellingen O; Rodermond HM; Verhoeff JJ; Lascano V; Daalhuisen JB; Medema JP; Sprick MR
Oncogene; 2013 Mar; 32(12):1539-48. PubMed ID: 22614016
[TBL] [Abstract][Full Text] [Related]
4. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram.
Triscott J; Rose Pambid M; Dunn SE
Stem Cells; 2015 Apr; 33(4):1042-6. PubMed ID: 25588723
[TBL] [Abstract][Full Text] [Related]
5. [Progress in the study of brain tumor stem cells as treatment targets].
Hide T; Kuratsu J
Brain Nerve; 2009 Jul; 61(7):781-9. PubMed ID: 19618855
[TBL] [Abstract][Full Text] [Related]
6. Targeting glioblastoma cancer stem cells: the next great hope?
Khan IS; Ehtesham M
Neurosurg Focus; 2014 Dec; 37(6):E7. PubMed ID: 25581936
[TBL] [Abstract][Full Text] [Related]
7. Brain tumor stem cells as research and treatment targets.
Hide T; Takezaki T; Nakamura H; Kuratsu J; Kondo T
Brain Tumor Pathol; 2008; 25(2):67-72. PubMed ID: 18987831
[TBL] [Abstract][Full Text] [Related]
8. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
9. Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review).
Bryukhovetskiy I; Ponomarenko A; Lyakhova I; Zaitsev S; Zayats Y; Korneyko M; Eliseikina M; Mischenko P; Shevchenko V; Shanker Sharma H; Sharma A; Khotimchenko Y
Int J Mol Med; 2018 Aug; 42(2):691-702. PubMed ID: 29749540
[TBL] [Abstract][Full Text] [Related]
10. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility.
Bajetto A; Porcile C; Pattarozzi A; Scotti L; Aceto A; Daga A; Barbieri F; Florio T
J Biol Regul Homeost Agents; 2013; 27(1):143-54. PubMed ID: 23489694
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy targeting glioma stem cells--insights and perspectives.
Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
[TBL] [Abstract][Full Text] [Related]
12. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
Kim SS; Harford JB; Pirollo KF; Chang EH
Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
[TBL] [Abstract][Full Text] [Related]
13. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
[TBL] [Abstract][Full Text] [Related]
14. The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells.
Bou-Gharios J; Assi S; Bahmad HF; Kharroubi H; Araji T; Chalhoub RM; Ballout F; Harati H; Fares Y; Abou-Kheir W
Pharmacol Rep; 2021 Feb; 73(1):227-239. PubMed ID: 33140310
[TBL] [Abstract][Full Text] [Related]
15. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme.
Broadley KW; Hunn MK; Farrand KJ; Price KM; Grasso C; Miller RJ; Hermans IF; McConnell MJ
Stem Cells; 2011 Mar; 29(3):452-61. PubMed ID: 21425408
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma and stem cells.
Altaner C
Neoplasma; 2008; 55(5):369-74. PubMed ID: 18665745
[TBL] [Abstract][Full Text] [Related]
17. The role of cancer stem cells (CD133(+)) in malignant gliomas.
Cho DY; Lin SZ; Yang WK; Hsu DM; Lin HL; Lee HC; Lee WY; Chiu SC
Cell Transplant; 2011; 20(1):121-5. PubMed ID: 20887676
[TBL] [Abstract][Full Text] [Related]
18. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
Reddy RG; Bhat UA; Chakravarty S; Kumar A
Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
[TBL] [Abstract][Full Text] [Related]
19. The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma.
Tallman MM; Zalenski AA; Deighen AM; Schrock MS; Mortach S; Grubb TM; Kastury PS; Huntoon K; Summers MK; Venere M
Cancer Lett; 2021 Feb; 499():232-242. PubMed ID: 33253788
[TBL] [Abstract][Full Text] [Related]
20. Frontiers in targeting glioma stem cells.
Frosina G
Eur J Cancer; 2011 Mar; 47(4):496-507. PubMed ID: 21185169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]